{"name":"Neurocrine UK Limited","slug":"neurocrine-uk-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Chronocort","genericName":"Chronocort","slug":"chronocort","indication":"Other","status":"discontinued"},{"name":"Cortef","genericName":"Cortef","slug":"cortef","indication":"Other","status":"marketed"},{"name":"DITEST","genericName":"DITEST","slug":"ditest","indication":"Other","status":"phase_1"},{"name":"Infacort®","genericName":"Infacort®","slug":"infacort","indication":"Adrenal insufficiency (primary, secondary, and tertiary)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Hydrocortisone Modified Release Capsules","genericName":"Hydrocortisone Modified Release Capsules","slug":"hydrocortisone-modified-release-capsules","indication":"Eczema","status":"phase_2"},{"name":"standard glucocorticoid therapy","genericName":"standard glucocorticoid therapy","slug":"standard-glucocorticoid-therapy","indication":"Severe allergic reactions","status":"phase_3"}]}],"pipeline":[{"name":"Chronocort","genericName":"Chronocort","slug":"chronocort","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cortef","genericName":"Cortef","slug":"cortef","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DITEST","genericName":"DITEST","slug":"ditest","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hydrocortisone Modified Release Capsules","genericName":"Hydrocortisone Modified Release Capsules","slug":"hydrocortisone-modified-release-capsules","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Eczema","Psoriasis","Rheumatoid arthritis"],"catalyst":""},{"name":"Infacort®","genericName":"Infacort®","slug":"infacort","phase":"phase_3","mechanism":"Infacort is a modified-release hydrocortisone formulation designed to mimic the natural circadian rhythm of cortisol secretion in patients with adrenal insufficiency.","indications":["Adrenal insufficiency (primary, secondary, and tertiary)"],"catalyst":""},{"name":"standard glucocorticoid therapy","genericName":"standard glucocorticoid therapy","slug":"standard-glucocorticoid-therapy","phase":"phase_3","mechanism":"Glucocorticoids reduce inflammation and suppress the immune system by binding to glucocorticoid receptors.","indications":["Severe allergic reactions","Autoimmune disorders such as rheumatoid arthritis and lupus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOTU5OWGVtVElBSkN3RE9LV2FjMkNyMTlfaWp0VDJkMXVqOXhZV2FMaXZIOUh3RWJCVWlsODVqa0JDZHlSUElKdUJiZEJVMXhqOHNJWG0tZ1p3bWZBUng2TzJtZ1RLSy1mTTJkSTJfNmhjeHI5M1FiREltMDlrT25KSEVKcGVwdmw5?oc=5","date":"2026-04-07","type":"pipeline","source":"pharmaphorum","summary":"Neurocrine pays $2.9bn for Soleno and extreme hunger drug - pharmaphorum","headline":"Neurocrine pays $2.9bn for Soleno and extreme hunger drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNMk9KTThLU1RNUXlUUHJBWUt1MF9RcmZRQnZkUDc4X0N0MHBUcEpUM2xGN0J5YndSSmxnLXoxRW0wcEFvSmM5akVOZ0wzOHpiakM0T3ZLd2JJdWdWajV2VnRlQlpNek9NNElQWURBRnNVc2ZsWWo0V2FuVlRGNmVWV2xfOVhNZw?oc=5","date":"2026-02-12","type":"pipeline","source":"Business Weekly","summary":"Nxera Pharma rebuild starting to pay off - Business Weekly","headline":"Nxera Pharma rebuild starting to pay off","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPSlRPdVRhREZNcFc2cVRldkxSZVBZYjlvNTUxaXd4Mkh6eGhMYzNvbUdfRUZQeTh2V1FvbjRQZHIzRmRYQ204c1I1NWlVV3Faa3FWRDloX0pjQWxBdnctYUhRRUQzZFhWRmRCa1BUWDNLRDh6VnZCSDhDb3BrRnk2Y0xXWlpsNXBBNWZ6Y25DdGt4RFJvY3Zz?oc=5","date":"2025-10-17","type":"regulatory","source":"lupin.com","summary":"Lupin Receives Approval from U.S. FDA for Valbenazine Capsules - lupin.com","headline":"Lupin Receives Approval from U.S. FDA for Valbenazine Capsules","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQUndiV1pxNVZuRXE4Q3I2OTdDc2ZxM2RsWllRa2FZTmdJU2YwdUo1djRmajRPYk9kd243aXpFWmdSMEpFTzl6bVlvMkxWSXk1TnhYTDNxdFA0T2xRelNkN1NDcEVSYy1BNkZianMxeHhEbFpLQU9XeUE0ODhyWEIxS1hXdEdpRHNldzlRa2pwR1RCbkJiRHJiOA?oc=5","date":"2025-08-01","type":"pipeline","source":"Community Pharmacy England","summary":"10 products re-classified as special containers from August 2025 - Community Pharmacy England","headline":"10 products re-classified as special containers from August 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOOFczcy02YzhVVF9HN1VndnhNNGhKZHVTaEpLRVFvdnpwUlhDUXBwWnQwNndIUkQ2Sk8wRG1qM0xXQlVxVXpBVE1ZRzJTNkhESkhkeHVIdGdHa0pGbXJQazlqNHpQUFJMSHZuWmcxOE9RWmduczFyODlRYWRRX3p3R1p4SjZQUUJFc0U3bjBMSVBqQ1ZpQ1NVM2JvZDZFM3NSZVZqRGpZazZHMHRiaGFsM0NJcHRoZndsNFEyUDdFRHlsZEtwMFFxX3VRbHNuLWVIR3FqZDFoNUdxcUwxZlQySS12Vld3aldCaEhLSUtPWDZDSlZyTzVpWlMtdlE5V2hUMGhWeVFmaXdRbmEwbEhpMk51NFNNa2ROMnMwakxQWk1qRFhSX0tKUEJ0VQ?oc=5","date":"2025-06-02","type":"pipeline","source":"GlobeNewswire","summary":"Nxera Pharma to Receive US$15 Million from Neurocrine - GlobeNewswire","headline":"Nxera Pharma to Receive US$15 Million from Neurocrine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNM3BXTW1BYVk5MlJtYnZTOWlpYVhrSG9vS1BRWXdSVnpFUEppTy1yWmJ3dmlIYTJqeGFNbTBfaUpEZldZdlZLMEtFX3UyMkxrbzdTT09RTzA5czNzN3h0ZDFYd09RS2pySnE2bWdhZmFFSWVkeDRETHBHTFhzQTZkNF80MlFsVUUzck56dnJYaGRDNkJpQXR3U1JZUDlfRWJ4dDkyZkhISnlRSDhBdmVHZQ?oc=5","date":"2025-06-02","type":"pipeline","source":"Business Weekly","summary":"Nxera wins $15m from Neurocrine Biosciences via schizophrenia drug dosing - Business Weekly","headline":"Nxera wins $15m from Neurocrine Biosciences via schizophrenia drug dosing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxON1p2S1VrcG9sbDBsZ25KbzJ5R3VGSV9FYUxTRXl2Q0xHal9NN3ZqMHdsTVRxcE9rLVphbnJzdk5aMHU2eWZCZzExdUE4VmNMTHYwRjJWeVZVNmRROTBpWXNzT3BsdHA5d0xVUURNWS1FbS1yWEd1ZE1YdVktY3BPRGFzVjg2TlNMQjFvVENmd3pONXozdnpSeDFJMFo0STduaV9mcGln?oc=5","date":"2024-08-21","type":"pipeline","source":"Fortune Business Insights","summary":"Top 5 Huntingtons Disease Treatment Provider Companies - Fortune Business Insights","headline":"Top 5 Huntingtons Disease Treatment Provider Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQTW9LTkszRURQdDRtYllPTnpzeF84TUVCckxyYk5kTS1tUUt6R3c0MlI1alNlVHFzY1Q0Y0dWRmhHLVRTaGtROW4xS2RNNXdLd2E1OHJjcjlDOV9hVWVhYk10b05JTGx4azdDSElyeUI0TnZOQ0phLUFWYmVNbDhWeXZ3aDJHQlRNcGUwRnhzR0c2RkJlYk1qTWhXQTU?oc=5","date":"2024-07-01","type":"regulatory","source":"The Pharma Letter","summary":"Boosting crinecerfont, Neurocrine draws from gamut of FDA support - The Pharma Letter","headline":"Boosting crinecerfont, Neurocrine draws from gamut of FDA support","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNSW02YlFxc0x1ZFIwLVo0bnI0NDVUY3Jjd3FVNG9rZ181T3MySHExaTdPdDhhX3p6azVoOG1WbDBnZ2hkV2JaT1Y5ajJVbTFWa0pYS0p0ZGlxWVFHSm8tOEFrbnVEREhDNlBCaEVmREMzbVNpa3BIOGFuNGk3aGVfekEtN2s5MjBQc3hpZndXR0E2X1I1ZTYyeW1oM0E?oc=5","date":"2022-08-30","type":"deal","source":"Fierce Pharma","summary":"Amid launch efforts, Neurocrine doles out £48M to acquire small UK biotech Diurnal - Fierce Pharma","headline":"Amid launch efforts, Neurocrine doles out £48M to acquire small UK biotech Diurnal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQbGFmWVp6MWRXWTFVdXhtWmdtcFZFMGdfRnZZaEt2VGhBWkJRT3Z0alR4MkdGTmFUa0ZCaWpSaGo4NlJOLU54d2J4Yk4wdUktdHdVaUhMOC1WTG1fdjZSWXc2UVgyQUw4bWlFbjhKR0tKSUZWRXNHZXEwUy1OcTJ1eTFfYTNlV3hDZDZiQlNn?oc=5","date":"2022-08-30","type":"deal","source":"BioPharma Dive","summary":"Neurocrine, with latest deal, gets a foothold in Europe - BioPharma Dive","headline":"Neurocrine, with latest deal, gets a foothold in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOLWNocU0yTVZBVl8zMzFHbXVkWWdPNVltNk9YUUtDRjJsZ2FiOFJiRFF4RGJUNmVkbjJqQzI3VjRxWmhkaDY1ZGxoR2MwWEZXOVBSb0J1TFoxOWdZUDRHQlNJX2RhLUZSeHB6RzVueUdIWkhtRWJvdFdUM1lCMnhjU3dMZ0RTb0YxckllNTBYVQ?oc=5","date":"2022-08-30","type":"pipeline","source":"pharmaphorum","summary":"Neurocrine Bio agrees $57m takeover of UK biotech Diurnal - pharmaphorum","headline":"Neurocrine Bio agrees $57m takeover of UK biotech Diurnal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPejRMRGVyWkJxM2o5bFk2dFlMMkZGLVJFV2F4NEVaaUk5YksyT0QtaExka1dna3lRY0xPdFl3RmE3RXVEcXJpa25ScGlTX3lFTkdvaDgwTm8yS2gzNHpORmZRSGlyc2sweDItbXZwbmM2Ri1CUGotczdEYm1FN2RlNjFGZTJPcjFDZDBlT1RLTk85Zw?oc=5","date":"2020-04-24","type":"pipeline","source":"BioPharma Dive","summary":"Launch for Neurocrine Parkinson’s drug put on hold because of coronavirus - BioPharma Dive","headline":"Launch for Neurocrine Parkinson’s drug put on hold because of coronavirus","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"discontinued":1,"marketed":1,"phase_1":1,"phase_2":1,"phase_3":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}